Free shipping on all orders over $ 500

Atabecestat

Cat. No. M10943
Atabecestat Structure
Synonym:

JNJ-54861911

Size Price Availability Quantity
5mg USD 445  USD445 In stock
10mg USD 740  USD740 In stock
50mg USD 2200  USD2200 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

Atabecestat (JNJ-54861911) is a potent brain-osmotic and has oral activity β-position amyloid precursor protein lyase 1 (BACE1 inhibitors that strongly reduce the expression of Aβ protein in cerebrospinal fluid. Atabecestat (JNJ-54861911) is tolerant and has sustained pharmacokinetic (PK) and pharmacodynamic (PD) profiles. Atabecestat (JNJ-54861911) has the potential to be used in the study of Alzheimer's disease.

Chemical Information
Molecular Weight 367.4
Formula C18H14FN5OS
CAS Number 1200493-78-2
Solubility (25°C) DMSO ≥ 200 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
Conversion of different model animals based on BSA (PMID: 27057123)
Species Mouse Rat Rabbit Guinea pig Hamster Dog
Weight (kg) 0.02 0.15 1.8 0.4 0.08 10
Body Surface Area (m2) 0.007 0.025 0.15 0.05 0.02 0.5
Km factor 3 6 12 8 5 20
Animal A (mg/kg) = Animal B (mg/kg) multiplied by  Animal B Km
Animal A Km

For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.

References

[1] Yuji Koriyama, et al. J Med Chem. Discovery of Atabecestat (JNJ-54861911): A Thiazine-Based β-Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor Advanced to the Phase 2b/3 EARLY Clinical Trial

[2] Reisa Sperling, et al. JAMA Neurol. Findings of Efficacy, Safety, and Biomarker Outcomes of Atabecestat in Preclinical Alzheimer Disease: A Truncated Randomized Phase 2b/3 Clinical Trial

[3] Paul J Thomson, et al. Allergy. Drug-specific T-cell responses in patients with liver injury following treatment with the BACE inhibitor atabecestat

[4] Gerald Novak, et al. Alzheimers Res Ther. Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study

[5] Maarten Timmers, et al. Alzheimers Res Ther. Pharmacodynamics of atabecestat (JNJ-54861911), an oral BACE1 inhibitor in patients with early Alzheimer's disease: randomized, double-blind, placebo-controlled study

Related BACE Products
Se-Methylselenocysteine hydrochloride

Se-Methylselenocysteine hydrochloride, a precursor of Methylselenol, has potent cancer chemopreventive activity and anti-oxidant activity.

Glabrolide

Glabrolide, derived from Glycyrrhiza uralensis Fisch., is a β-secretase 1 (BACE-1) inhibitor.

Kushenol C

Kushenol C, isolated from the roots of Sophora flavescens, shows anti-Inflammatory and anti-oxidative stress activities. Kushenol C inhibits BACE1 (β-site APP cleaving enzyme 1) with an IC50 of 5.45 µM.

Deoxyneocryptotanshinone

Deoxyneocryptotanshinone is a high affinity BACE1 (Beta-secretase) inhibitor with an IC50 value of 11.53 μM. Deoxyneocryptotanshinone shows a promising dose-dependent inhibition of protein tyrosine phosphatase 1B (PTP1B) with an IC50 value of 133.5 μM.

β-Secretase Inhibitor IV

β-Secretase Inhibitor IV is a cellular permeability inhibitor that binds to the active site of BACE-1 and blocks its proteolytic activity (IC₅₀= 15 nM in human BACE-1).

  Catalog
Abmole Inhibitor Catalog




Keywords: Atabecestat, JNJ-54861911 supplier, BACE, inhibitors, activators


Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.